EP Patent

EP3495367A1 — Substituted tricyclic compounds as fgfr inhibitors

Assigned to Incyte Holdings Corp · Expires 2019-06-12 · 7y expired

What this patent protects

The present invention relates to tricyclic compounds of formula (II) and their use for the treatment of fibrotic diseases.

USPTO Abstract

The present invention relates to tricyclic compounds of formula (II) and their use for the treatment of fibrotic diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3495367A1
Jurisdiction
EP
Classification
—
Expires
2019-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.